CA
NZ
UK
AU
IND
US
• Non-Negotiable Regulatory Step: Biocompatibility testing under ISO 10993 is a required prerequisite before FDA submission for devices like NASARIX.
• Acceptable Safety Profile Confirmed at ASCO: Phase 3 safety data presented at ASCO demonstrated acceptable safety across all combination cohorts with no new safety signals identified.
• Major Price Target Increase: Chardan Capital raised its EyePoint Pharmaceuticals (NASDAQ: EYPT) target to $65 from $29, a 124% jump, while maintaining a Buy rating.
• Muscle Metabolism Is a Growing Drug Target: ANT1 modulation addresses mitochondrial energy function in muscle — relevant across sarcopenia, myopathy, and chronic disease-related muscle weakness.
• Phase 1/2 Trial Initiated July 2, 2026: Molecular Partners initiated the Phase 1/2 trial for [212Pb]Pb-MP0712 on July 2, 2026, targeting DLL3-positive SCLC and other neuroendocrine tumors.
• Early Proof of Concept: PMGC Holdings' (NASDAQ: ELAB) 50% peak improvement in ANT1 expression offers an initial signal for its AI-driven discovery approach.
• Price Target More Than Doubled to $65: Chardan Capital raised its price target dramatically from $29 to $65, representing a more than 120% increase in the analyst's formal valuation.
• Price Target More Than Doubled: Chardan Capital raised its price target on EyePoint Pharmaceuticals (NASDAQ: EYPT) to $65 from $29, a jump of more than 120%.
• USPTO Notice of Allowance Granted: The USPTO granted a Notice of Allowance for a patent application covering methods for the treatment and inhibition of fibrosis.
• All ISO 10993 Safety Endpoints Met: NASARIX passed all biocompatibility safety tests to ISO 10993 and FDA standards including cytotoxicity and systemic toxicity.
Please wait processing your request...